We have located links that may give you full text access.
APOA4 as a novel predictor of prognosis in Stevens-Johnson syndrome/toxic epidermal necrolysis: a proteomics analysis from two prospective cohorts.
Journal of the American Academy of Dermatology 2023 March 23
BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening adverse drug reactions. Conventional systemic therapies are of limited efficacy and often exhibit strong side effects.
OBJECTIVE: To assess the efficacy and safety of the combination treatment with a tumor necrosis factor (TNF) - α antagonist adalimumab and delineate the underlying mechanisms.
METHODS: We evaluated the efficacy and safety of the combination therapy with adalimumab by comparing two treatment cohorts of SJS/TEN patients. Patient plasma samples were collected for proteomics analysis.
RESULTS: The combination therapy with adalimumab significantly shortened the time to mucocutaneous reepithelization and healing, with reduced side effects caused by corticosteroids. Plasma proteomic profiling showed that apolipoprotein A-Ⅳ (APOA4) was one of the most significant differentially expressed proteins. Multivariate regression analysis revealed that APOA4 level was significantly associated with prognosis parameter of SJS/TEN (P=0.004), but not with disease severity score (SCORTEN) (P=0.118). Thus further research will be helpful to effectively incorporate APOA4 into current SCORTEN-driven protocols.
LIMITATIONS: The cohort size is relatively small. Both cohorts had low overall SCORTEN scores.
CONCLUSION: Adalimumab in combination with corticosteroids demonstrates significant clinical benefits over corticosteroids alone in SJS/TEN patients. Moreover, APOA4 may serve as a novel prognostic marker of SJS/TEN.
OBJECTIVE: To assess the efficacy and safety of the combination treatment with a tumor necrosis factor (TNF) - α antagonist adalimumab and delineate the underlying mechanisms.
METHODS: We evaluated the efficacy and safety of the combination therapy with adalimumab by comparing two treatment cohorts of SJS/TEN patients. Patient plasma samples were collected for proteomics analysis.
RESULTS: The combination therapy with adalimumab significantly shortened the time to mucocutaneous reepithelization and healing, with reduced side effects caused by corticosteroids. Plasma proteomic profiling showed that apolipoprotein A-Ⅳ (APOA4) was one of the most significant differentially expressed proteins. Multivariate regression analysis revealed that APOA4 level was significantly associated with prognosis parameter of SJS/TEN (P=0.004), but not with disease severity score (SCORTEN) (P=0.118). Thus further research will be helpful to effectively incorporate APOA4 into current SCORTEN-driven protocols.
LIMITATIONS: The cohort size is relatively small. Both cohorts had low overall SCORTEN scores.
CONCLUSION: Adalimumab in combination with corticosteroids demonstrates significant clinical benefits over corticosteroids alone in SJS/TEN patients. Moreover, APOA4 may serve as a novel prognostic marker of SJS/TEN.
Full text links
Related Resources
Trending Papers
Review article: Recent advances in ascites and acute kidney injury management in cirrhosis.Alimentary Pharmacology & Therapeutics 2024 March 26
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app